Related Experiment Video
Updated: Aug 15, 2026

08:43
Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
Bidirectional cross-modal attention with adaptive gating for multimodal alzheimer's disease classification
Xiaoli Yang1, Chenchen Wang1, Xiao Li1
1Henan University of Science and Technology, School of Medical Technology and Engineering, Luoyang, 471023, China.
Biomedical Physics & Engineering Express
|August 13, 2026
Summary
This study introduces a new deep learning framework combining brain imaging and clinical data for accurate Alzheimer's disease (AD) and mild cognitive impairment (MCI) diagnosis. The model shows high accuracy in classifying different stages of cognitive decline.
Area of Science:
- Neuroscience
- Artificial Intelligence
- Medical Imaging
Background:
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder.
- Mild cognitive impairment (MCI) is a transitional stage between cognitively normal (CN) and AD.
- Early diagnosis of AD and MCI is crucial for timely intervention and disease management.
Purpose of the Study:
- To develop a multimodal deep learning framework for improved classification of AD and MCI.
- To overcome limitations of single-modal approaches and enhance cross-modal interaction modeling.
- To integrate structural magnetic resonance imaging (sMRI) and clinical features for a comprehensive diagnostic tool.
Main Methods:
- Utilized a 3D ResNet-34 for sMRI feature extraction and a multilayer perceptron (MLP) for clinical data encoding.
- Implemented a bidirectional cross-modal attention mechanism to strengthen feature associations.
- Employed an adaptive gated fusion module for dynamic integration of multimodal features.
Main Results:
- Achieved high accuracy in multi-class classification: 95.67% ± 1.70% (CN vs. MCI vs. AD) and 93.64% ± 2.36% (CN vs. EMCI vs. LMCI vs. AD).
- Demonstrated strong performance in binary classifications, including AD vs. CN (96.83% ± 1.53%) and MCI vs. CN (95.83% ± 1.39%).
- Results were validated for robustness using five different random seeds, reported as mean ± standard deviation.
Conclusions:
- The proposed multimodal deep learning framework offers an effective solution for computer-aided diagnosis of AD and MCI.
- Integrating sMRI and clinical data with advanced deep learning techniques significantly improves classification accuracy.
- This approach holds promise for early and accurate detection of cognitive impairment, aiding in disease progression management.
Related Concept Videos
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
